Sentinel lymph node biopsy in pregnancy-associated breast cancer

Zoltán Mátrai, Ferenc Bánhidy, Melinda Téglás, Eszter Kovács, Ákos Sávolt, Nóra Udvarhelyi, Alexandra Bartal, Miklós Kásler

Research output: Contribution to journalArticle

4 Citations (Scopus)


The incidence of pregnancy-associated breast cancer is rising. Sentinel lymph node biopsy is the method of choice in clinically node negative cases as the indicated minimally invasive regional staging procedure. Some reports have linked radioisotope and blue dye required for lymphatic mapping to teratogenic effects, the idea of which has become a generalized statement and, until recently, contraindication for these agents was considered during pregnancy. Today, there are many published reports of successful interventions with low-dose 99mTc-labeled human albumin nanocolloid, based on dosimetric modeling demonstrating a negligible radiation exposure of the fetus. These results contributed to the seemingly safe and successful use of sentinel lymph node biopsy during pregnancy, though generally it can not replace axillary lymphadenectomy in the absence of high-quality evidence. The possibility of sentinel lymph node biopsy should be offered to pregnancy-associated early breast cancer patients with clinically negative axilla, and patients should be involved in the decision making following extensive counselling. This paper presents the successful use of sentinel lymph node biopsy with low-dose tracer during two pregnancies (in the first and third trimesters) and, for the first time in Hungarian language, it offers a comprehensive literature review on this topic. Orv. Hetil., 154(50), 1991-1997.

Original languageEnglish
Pages (from-to)1991-1997
Number of pages7
JournalOrvosi hetilap
Issue number50
Publication statusPublished - Dec 1 2013


  • Pregnancy-associated breast cancer
  • Sentinel lymph node biopsy
  • Tc-labeled human albumin

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Sentinel lymph node biopsy in pregnancy-associated breast cancer'. Together they form a unique fingerprint.

  • Cite this